|1.||Kastelein, John J P: 6 articles (11/2012 - 04/2007)|
|2.||Shear, Charles L: 6 articles (11/2012 - 03/2007)|
|3.||Schaefer, Ernst J: 4 articles (06/2013 - 05/2005)|
|4.||Duggan, William T: 4 articles (11/2012 - 03/2007)|
|5.||Barter, Philip J: 4 articles (11/2012 - 04/2007)|
|6.||Revkin, James H: 4 articles (07/2007 - 03/2007)|
|7.||Rye, Kerry-Anne: 3 articles (11/2012 - 08/2011)|
|8.||Hermann, Matthias: 3 articles (07/2012 - 01/2009)|
|9.||Tardif, Jean-Claude: 3 articles (08/2011 - 03/2007)|
|10.||Asztalos, Bela F: 3 articles (12/2007 - 05/2005)|
|1.||Coronary Disease (Coronary Heart Disease)
01/01/2007 - "Will torcetrapib be the next big thing in coronary heart disease risk reduction?"
06/01/2013 - "Two CETP inhibitors, dalcetrapib and torcetrapib, have been tested in large clinical trials in statin-treated coronary heart disease patients and have shown no clinical benefit compared to placebo. "
07/01/2007 - "A large clinical trial in coronary heart disease patients on atorvastatin was recently stopped prematurely because of excess mortality in those receiving torcetrapib vs. placebo and two other trials reported no benefit of torcetrapib on coronary atherosclerosis or carotid artery intimal medial thickness as compared with subjects on atorvastatin alone. "
01/01/2010 - "The linear relationship between LDL-cholesterol lowering and reduction in coronary heart disease risk, as well as a lack of conclusive evidence for other mechanisms of action raise the question of whether any cholesterol-lowering agent is equally effective for reducing cardiovascular risk, but recent data from the torcetrapib clinical trial programme suggest this is not the case. "
12/01/2013 - "However, several recent clinical trials using HDL cholesterol-raising agents, such as torcetrapib, dalcetrapib, and niacin, did not demonstrate a significant reduction of cardiovascular events in patients with coronary disease. "
09/01/2010 - "Imaging studies with torcetrapib failed to show an effect on atherosclerosis in humans, probably because of the off-target effect on the RAAS. "
01/01/2010 - "Clinical trials were however disappointing, as torcetrapib increased mortality and did not reduce the progression of atherosclerosis. "
02/01/2009 - "Despite intriguing antiatherogenic effects of CETP inhibition in animal models of atherosclerosis, the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events trial investigators observed an excess of cardiovascular and noncardiovascular morbidity and mortality associated with the use of the CETP inhibitor torcetrapib. "
08/01/2008 - "In a phase 3 clinical study, evaluating the effects of torcetrapib in atherosclerosis, there was an excess of deaths and adverse cardiovascular events in patients taking torcetrapib. "
04/01/2006 - "Upcoming results from Phase III trials of torcetrapib should provide anatomical measurements of atherosclerosis and thus the first assessment of therapeutic benefit."
|3.||Coronary Artery Disease (Coronary Atherosclerosis)
12/03/2007 - "However, results from recent clinical trials question the therapeutic use of at least 1 CETP inhibitor, torcetrapib (Pfizer Inc, New York, NY), which was demonstrated to increase blood pressure and have no effect on decreasing the progression of coronary atherosclerosis. "
12/09/2008 - "The majority of torcetrapib-treated patients demonstrated no regression of coronary atherosclerosis. "
02/01/2008 - "Torcetrapib and the progression of coronary atherosclerosis."
03/29/2007 - "Effect of torcetrapib on the progression of coronary atherosclerosis."
12/03/2007 - "A large clinical trial in patients with CAD who were taking atorvastatin was recently stopped prematurely because of excess mortality in those receiving torcetrapib versus placebo, and 2 other trials reported no benefit of torcetrapib on coronary atherosclerosis or carotid intima-media thickness as compared with subjects on atorvastatin alone. "
|4.||Cardiovascular Diseases (Cardiovascular Disease)
05/01/2010 - "Given the well-documented association of endothelial dysfunction with cardiovascular disease and risk, this activity of torcetrapib may have contributed to increased cardiovascular risk in clinical trials."
11/13/2012 - "Torcetrapib, an inhibitor of CETP, increased risk of death and ischemic cardiovascular disease of those randomized to the drug, despite improving the lipid profile. "
01/01/2006 - "The raising HDL-cholesterol with torcetrapib could be a new approach to atherosclerotic cardiovascular disease although new trials based on hard clinical end points are necessary."
01/01/2009 - "Treatment with the cholesterol ester transfer protein (CETP) inhibitor and HDL-increasing drug torcetrapib resulted in increased risk of cardiovascular disease. "
08/01/2008 - "Cholesteryl ester transfer protein inhibition with torcetrapib does not benefit cardiovascular disease; whether this is related to 'congestion' of HDL transport or a specific off-target vasopressor effect remains unclear. "
|5.||Atherosclerotic Plaque (Atheroma)
09/01/2012 - "However, use of the CETP inhibitor torcetrapib in humans did not reduce atheroma in three imaging trials and caused an excess of deaths and cardiovascular events in a large clinical outcome trial. "
11/16/2009 - "The CETP inhibitor torcetrapib was investigated in humans in imaging trials that failed to demonstrate an effect on atheroma in either the carotid or coronary arteries. "
10/01/2007 - "Two of these studies examined carotid intima-medial thickness and one examined coronary artery atheroma load and none of the studies found a significant benefit in favour of torcetrapib therapy. "
12/09/2008 - "In torcetrapib-treated patients, an inverse relationship was observed between changes in HDL-C and percentage atheroma volume (r=-0.17, P<0.001). "
12/09/2008 - "Despite substantial increases in HDL-C, no effect was found of torcetrapib on percent atheroma volume. "
|5.||Niacin (Nicotinic Acid)
|9.||Cholesterol Ester Transfer Proteins